Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Flexible dosing of bortezomib for multiple myeloma

IMW 2011

Published: 20 May 2011

Views: 5898

Rating:

Save

Prof Michel Delforge - Catholic University, Leuven, Belgium

Prof Delforge discusses giving bortezomib (Velcade) once a week and subcutaneously rather than intravenously. This is important to better manage toxicities especially in elderly patients. Talking at the International Myeloma Workshop, Paris, 5th May 2011.

Related Videos

Understanding cognitive impairment for elderly patients undergoing CAR T therapy

Dr Ashley Rosko - The Ohio State University, Columbus, USA

Understanding cognitive impairment for elderly patients undergoing CAR T therapy ( Dr Ashley Rosko - The Ohio State University, Columbus, USA )

SIOG 2024: Updates in haematology

Dr Ashley Rosko - The Ohio State University, Columbus, USA

SIOG 2024: Updates in haematology ( Dr Ashley Rosko - The Ohio State University, Columbus, USA )

Expectations and priorities of older patients with cancer: the PRIORITY...

Dr Camille Chakiba - Institute Bergonié, Bordeaux, France

Expectations and priorities of older patients with cancer: the PRIORITY multicenter cohort study ( Dr Camille Chakiba - Institute Bergonié, Bordeaux, France )

New classification for identifying HR myeloma based on cytogenetic abnormalities

Dr Jill Corre - IUCT Oncopole, Toulouse, France

New classification for identifying HR myeloma based on cytogenetic abnormalities ( Dr Jill Corre - IUCT Oncopole, Toulouse, France )

Daratumumab, bortezomib/thalidomide/dexamethasone (D-VTd) and DARA maintenance...

Dr Jill Corre - IUCT Oncopole, Toulouse, France

Daratumumab, bortezomib/thalidomide/dexamethasone (D-VTd) and DARA maintenance shows benefit in transplant-eligible NDMM ( Dr Jill Corre - IUCT Oncopole, Toulouse, France )

Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new...

Prof Xavier Leleu - CHU de Poitiers, Poitiers, France

Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new standard of care for NDMM TI non-frail patients ( Prof Xavier Leleu - CHU de Poitiers, Poitiers, France )

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM

Dr Elias Mai - Heidelberg University, Heidelberg, Germany

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM ( Dr Elias Mai - Heidelberg University, Heidelberg, Germany )

Use of bispecifics and CAR T cells in South America

Dr Natalia Schütz - Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

Use of bispecifics and CAR T cells in South America ( Dr Natalia Schütz - Hospital Italiano de Buenos Aires, Buenos Aires, Argentina )

Revolutionising myeloma treatment through immune profiling

Dr Romanos Sklavenitis-Pistofidis - Dana-Farber Cancer Institute, Boston, USA

Revolutionising myeloma treatment through immune profiling ( Dr Romanos Sklavenitis-Pistofidis - Dana-Farber Cancer Institute, Boston, USA )

More from ecancer